
Pharmacally
Foundayo
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Foundayo
Health TidingsLilly Expands Zepbound and Foundayo Access Through Hims & HersEli Lilly has partnered with Hims & Hers Health to expand access to its FDA-approved obesity medicines, Zepbound and Foundayo, through the telehealth platform.Fact-Checked
Clinical TrialsLilly’s Oral GLP-1 Foundayo Shows Clear Edge Over Oral SemaglutideNew Phase 3 ACHIEVE data showed that Lilly’s oral GLP-1 receptor agonist Foundayo (orforglipron) delivered greater reductions in HbA1c and body weight than oral semaglutide, while also outperforming…Fact-Checked
Health TidingsFoundayo Shows Consistent Weight Loss Across Menopause Stages in Phase 3 ATTAIN StudiesPost‑hoc analyses from Lilly’s Phase 3 ATTAIN program show that Foundayo, a once‑daily oral GLP‑1 receptor agonist, produced clinically meaningful weight loss and waist circumference reductions in women…Fact-Checked
Clinical TrialsEli Lilly’s Foundayo Shows Up to 13% Weight Loss in Older Adults in ATTAIN TrialsEli Lilly reported new Phase 3 data at ECO 2026 demonstrating that older adults treated with Foundayo (orforglipron) achieved clinically meaningful weight loss across the ATTAIN‑1 and ATTAIN‑2…Fact-Checked
Clinical TrialsLilly Reports Long-Term Weight Maintenance Data for Foundayo and Zepbound at ECO 2026New Phase 3b data from Lilly showed that patients with obesity maintained most prior weight loss with either continued Zepbound therapy or a switch to oral Foundayo after…Fact-Checked
Drugs Safety AlertFDA Requires Extensive Postmarketing Safety Data for FoundayoFDA approval of Foundayo (orforglipron) includes mandated pediatric studies, pregnancy registries, and long-term surveillance for medullary thyroid carcinoma, cardiovascular events, and liver safety risks.Fact-Checked
Health TidingsLilly Expands Obesity Portfolio With Foundayo Market LaunchEli Lilly and Company has launched Foundayo (orforglipron) in the U.S. for chronic weight management following FDA approval.Fact-Checked
Clinical TrialsNovo Nordisk’s Indirect Comparison Data from ORION Puts Wegovy Pill and Foundayo in FocusNovo Nordisk has released ORION study results shortly after Foundayo’s FDA approval, reporting superior weight loss and lower discontinuation rates with oral semaglutide versus orforglipron in an indirect…Fact-Checked
New Drug ApprovalLilly Brings Weight-Loss Pill to Market with Foundayo FDA ApprovalFDA approves Lilly’s once-daily oral GLP-1 Foundayo for obesity, showing strong Phase 3 weight loss and positioning it as a key rival in the emerging Wegovy pill segment.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.